Abstract
949P - First-line pembrolizumab (pembro) monotherapy in advanced clear cell renal cell carcinoma (ccRCC): Updated follow-up for KEYNOTE-427 cohort A
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have